CytoDyn Inc (OTCMKTS:CYDY) saw a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 26,536,800 shares, an increase of 42.2% from the August 15th total of 18,666,200 shares. Based on an average trading volume of 11,729,600 shares, the days-to-cover ratio is presently 2.3 days.
CYDY has been the subject of several recent research reports. Zacks Investment Research lowered CytoDyn from a “hold” rating to a “sell” rating in a research report on Thursday, August 20th. HC Wainwright reissued a “hold” rating on shares of CytoDyn in a research report on Monday, August 17th.
CytoDyn stock traded down $0.03 during trading hours on Wednesday, hitting $4.09. 2,530,825 shares of the stock traded hands, compared to its average volume of 6,402,489. The firm’s 50 day moving average price is $4.17 and its 200-day moving average price is $3.42. The stock has a market capitalization of $2.33 billion, a price-to-earnings ratio of -19.48 and a beta of -1.08. CytoDyn has a 1 year low of $0.26 and a 1 year high of $10.01.
CytoDyn Inc, a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease.
Featured Article: What are the economic characteristics of a bear market?
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.